Business Context and Reporting Period
This Form 6-K filing by GSK plc (GSK) reports a transaction in the company's own shares. The filing date is May 8, 2025, covering a share repurchase executed on May 7, 2025. The transaction was conducted through Citigroup Global Markets Limited as part of an existing buyback programme established via a non-discretionary agreement on February 24, 2025.
Key Financial Metrics
The filing details a specific share repurchase event rather than comprehensive financial results. Key metrics for the transaction are as follows:
- Shares Purchased: 687,081 ordinary shares.
- Price Range: Lowest price paid was 1,374.00 GBp; highest price paid was 1,403.00 GBp.
- Average Price: Volume-weighted average price paid was 1,384.13 GBp.
- Treasury Shares: Following this purchase, GSK holds 207,597,195 ordinary shares in treasury.
- Shares in Issue: 4,107,649,307 ordinary shares (excluding treasury shares).
- Voting Rights: Total voting rights stand at 4,107,649,307.
The filing text does not provide clear values for revenue, profit, cash flow, margins, or debt levels, as this document is limited to reporting the share transaction.
Material Changes
Since the commencement of the current buyback programme on February 24, 2025, the Company has purchased an aggregate of 38,526,892 ordinary shares. The May 7 transaction represents the latest execution within this programme. There are no other material changes to the company's financial position or operations disclosed in this specific filing.
Guidance, Outlook, and Risks
The filing includes a standard cautionary statement regarding forward-looking statements. GSK notes that any projections are subject to risks and uncertainties that may cause actual results to differ materially. Investors are directed to the "Risk Factors" section in GSK's Annual Report on Form 20-F for 2024 and the Q1 Results for 2025 for a detailed description of these factors. No specific new guidance or management commentary regarding future performance is provided in this document.
Important Facts for Investors
- Verify the total number of voting rights (4,107,649,307) for compliance with disclosure thresholds under the Financial Conduct Authority's rules.
- Confirm the cumulative buyback volume of 38.5 million shares since February 24, 2025, to assess the remaining capacity of the current programme.
- Note that the purchased shares are held as Treasury shares and do not carry voting rights.
- Review the referenced 2024 Form 20-F and 2025 Q1 Results for comprehensive financial data and risk factors not included in this transaction report.